I invested in SpringWorks Therapeutics (SWTX) given their recent NDA submission for mirdametinib, targeting a rare disease with significant unmet medi...
Read More
I invested in SpringWorks Therapeutics (SWTX) given their recent NDA submission for mirdametinib, targeting a rare disease with significant unmet medical needs, which could lead to a substantial market opportunity and drive the stock price higher.